Posters

Aflibercept treatment for macular edema following branch retinal vein occlusion and thinning fovea

Poster Details

First Author: D.Muramatsu JAPAN

Co Author(s):    Y. Wakabayashi   M. Miura   S. Kawakami   K. Yamamoto   K. Umazume   H. Goto              

Abstract Details



Purpose:

To assess the efficacy of aflibercept treatment in Japanese patients with macular edema following branch retinal vein occlusion (BVO) and the frequency of thinning fovea.

Setting:

Tokyo Medical University Hospital Tokyo Medical University, Ibaraki Medical centre

Methods:

Retrospective case series. Nineteen cases of BVO who received intravitreal injection of aflibercpt (IVA) at Tokyo Medical University (TMU) hospital and TMU-Ibaraki Medical centre between June 2015 and December were enrolled. Ten eyes were anti-VEGF treatment naïve cases and 9 eyes were switched cases from ranibizumab. Treatment regimen was as-needed therapy. The main outcomes were BCVA (LogMAR) and CRT evaluated at 1, 3, 6 months and final visit after primary IVA and the percentage of thinning fovea.

Results:

The percentage of eyes that given single IVA or more than 2 IVA was 11% and 89%. The average number of IVA was 2.8±1.0 times. Baseline BCVA was 0.36 ±0.32. At 1, 3, 6 months and at the final visit, BCVA improved to 0.25±0.29, 0.20±0.26, 0.21±0.32 and 0.18±0.31 respectively. Three months and final VA were improved significantly. Baseline CRT was 556 ±191μm. CRT decreased significantly to 295μm ±86, 325 ±119, 323 ±93 and 286 ±108, respectively (p<0.01; t-test) However, thinning fovea cases with CRT less than 220 um was observed in 35%.

Conclusions:

IVA improved macular structure for patients with BVO for 6 months. Further research is needed for treatment regimen, especially for patients with thin CRT.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy